Market Research Reports

Atrial Fibrillation Market (Pharmacological and Non-Pharmacological Treatment, Electric Cardioversion, Radiofrequency, Cryo, Laser and Microwave Catheter Ablation, Maze Surgery, Anti-Coagulant and Anti-Arrhythmic Drugs) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019

88pages
Published Date: 2013-10-09
 

Description





Atrial fibrillation is a type of cardiac arrhythmia distinguished by an abnormal cardiac rhythm caused by a disturbance in heart’s electrical system. Atrial fibrillation (AF) is one of the most commonly occurring cardiac rhythm conditions. Being a potentially life threatening disease and expensive to treat, the overall healthcare system views the treatment for this condition as a strategically critical area to address. This report analyzes the market for atrial fibrillation market from the point of view of various pharmacological and non-pharmacological treatment products used for the treatment of AF. 

The pharmacological AF treatment market has been further classified into the specific drugs commonly used for treating AF, namely anti-arrythmics and anti-coagulants. The non-pharmacological atrial fibrillation devices market has been further sub-divided into therapeutic procedures such as catheter ablation procedures, maze surgery and electric cardioversion. The major methods of catheter ablation procedures studied in this report include radiofrequency, high intensity focused ultrasound (HIFU), cryoablation, microwave ablation and laser catheter ablation. Each of these segments and their sub-classification is analyzed on the basis of their market size and their forecast for the period 2011 to 2019, in terms of USD million. The compounded annual growth rate (CAGR) for all the above segments has been provided for the forecast period from 2013 o 2019, considering 2012 as the base year. 

In terms of geography, the market for atrial fibrillation treatment has been categorized into four geographical markets namely, North America, Europe, Asia-Pacific and Rest of the World (RoW). The market size and forecast for all the major segments, along with their growth rate, by regions has been provided in the report. The market overview section of the report includes the qualitative analysis of the atrial fibrillation treatment market in terms of environmental factors such as drivers, restraints and opportunities, market attractiveness analysis and Porter’s five forces analysis.

The report is concluded with the competitive landscape section which comprises the strategic recommendations for the current and future market players and company profiles of the existing market players in terms of their market share (value %) for the year 2012. Some of the major market players profiled in the report include St. Jude Medical, Boehringer Ingelheim, Boston Scientific Corporation, AtriCure, Inc., Johnson & Johnson and Bayer (Xeralto), Sanofi, CardioFocus, Endoscopic Technologies, Bristol Myers-Pfizer, Biosense Wesbter and others.

The global atrial fibrillation market is categorized into the following segments:
  • Atrial Fibrillation Market, by Treatment Types
    • Pharmacological Treatment
      • Anti-Arrhythmic Drugs
      • Anti-Coagulant Drugs
    • Non-Pharmacological Treatment
      • Catheter Ablation
        • Radiofrequency Based
        • Cryoablation Based
        • HIFU (High Intensity Focused Ultrasound) Based
        • Microwave Based
        • Laser Based
      • Maze Surgery
      • Electric Cardioversion
  • Atrial Fibrillation Market, by Geography
    • North America
    • Europe
    • Asia-Pacific
    • Rest of the World (RoW)

Table of Contents




Table of Content

Chapter 1 Preface
1.1 Report description
1.2 Market segmentation
1.3 Research methodology

Chapter 2 Executive Summary

Chapter 3 Market Overview
3.1 Introduction
3.2 Market Dynamics
      3.2.1 Drivers
              3.2.1.1 Rising global base of geriatric population
              3.2.1.2 Favorable results exhibited by clinical trials aimed at treating atrial fibrillation
              3.2.1.3 Rising prevalence of disorders such as hypertension and obesity accelerating the incidence rate of atrial fibrillation
      3.2.2 Restraints
              3.2.2.1 Stringent FDA, CE and European Medicines Agency product approval regulations
      3.2.3 Opportunities
              3.2.3.1 Introduction of innovative treatment procedures
              3.2.3.2 Rising prevalence of atrial fibrillation in emerging Asian economies
3.3 Porter’s Five Forces Analysis for the Global Atrial Fibrillation Market
      3.3.1 Bargaining Power of Suppliers
      3.3.2 Bargaining Power of Buyers
      3.3.3 Threat of Substitutes
      3.3.4 Threat of New Entrants
      3.3.5 Competitive Rivalry

Chapter 4 Atrial Fibrillation Market, by Treatment Types
4.1 Overview
      4.1.1 Global Atrial Fibrillation Market, 2011 – 2019 (USD Million)
4.2 Global Pharmacological Treatments for Atrial Fibrillation Market
      4.2.1 Global Pharmacological Treatment for Atrial Fibrillation Market, 2011 – 2019 (USD Million)
      4.2.2 Global Anti-Arrhythmic Drugs Market
              4.2.2.1 Global Anti-Arrhythmic Drugs Market, 2011 – 2019 (USD Million)
      4.2.3 Global Anti-Coagulants Market
              4.2.3.1 Global Anti-Coagulant Drugs for Atrial Fibrillation Market, 2011 – 2019 (USD Million)
4.3 Non-Pharmacological Treatment for Atrial Fibrillation Market
      4.3.1 Overview: Comparative Analysis of the Non-Pharmacological Treatment for Atrial Fibrillation Market
      4.3.2 Global Non-Pharmacological Treatment for Atrial Fibrillation Market, 2011 – 2019 (USD Million)
      4.3.3 Global Catheter Ablation Treatment for Atrial Fibrillation Market
              4.3.3.1 Overview
              4.3.3.2 Global Catheter Ablation Treatment for Atrial Fibrillation Market, 2011 – 2019 (USD Million)
              4.3.3.3 Global Radiofrequency Based Catheter Ablation Treatment for Atrial Fibrillation Market, 2011 – 2019 (USD Million)
              4.3.3.4 Global HIFU (High Intensity Focused Ultrasound) Based Catheter Ablation Treatment for Atrial Fibrillation Market, 2011 – 2019 (USD Million)
              4.3.3.5 Global Cryoablation Based Catheter Ablation Treatment for Atrial Fibrillation Market, 2011 – 2019 (USD Million)
              4.3.3.6 Global Microwave Based Catheter Ablation Treatment for Atrial Fibrillation Market, 2011 – 2019 (USD Million)
              4.3.3.7 Global Laser Based Catheter Ablation Treatment for Atrial Fibrillation Market, 2011 – 2019 (USD Million)
      4.3.4 Global Maze Surgery for Atrial Fibrillation Market, 2011 – 2019 (USD Million)
      4.3.5 Global Electric Cardioversion for Atrial Fibrillation Market, 2011 – 2019 (USD Million)

Chapter 5 Atrial Fibrillation Market, by Geography
5.1 Overview
5.2 North America
      5.2.1 North America Atrial Fibrillation Market, by Treatment Types, 2011 – 2019 (USD Million)
5.3 Europe
      5.3.1 Europe Atrial Fibrillation Market, by Treatment Types, 2011 – 2019 (USD Million)
5.4 Asia-Pacific
      5.4.1 Asia-Pacific Atrial Fibrillation Market, by Treatment Types, 2011 – 2019 (USD Million)
5.5 Rest of the World (RoW)
      5.5.1 RoW Atrial Fibrillation Market, by Treatment Types, 2011 – 2019 (USD Million)

Chapter 6 Competitive Landscape

Chapter 7 Recommendations
7.1 Investing in emerging markets, particularly China and Brazil
7.2 Focus on emerging technologies such as mini-maze procedure and catheter ablation

Chapter 8 Company Profiles
8.1 AtriCure, Inc.
      8.1.1 Company Overview
      8.1.2 Financial Overview
      8.1.3 Product Portfolio
      8.1.4 Business Strategies
8.2 Biosense Webster, Inc.
      8.2.1 Company Overview
      8.2.2 Product Portfolio
      8.2.3 Business Strategies
8.3 Boehringer Ingelheim GmbH
      8.3.1 Company Overview
      8.3.2 Financial Overview
      8.3.3 Product Portfolio
      8.3.4 Business Strategies
      8.3.5 Recent Developments
8.4 Boston Scientific Corporation
      8.4.1 Company Overview
      8.4.2 Financial Overview
      8.4.3 Product Portfolio
      8.4.4 Business Strategies
8.5 Bristol-Myers Squibb Corporation
      8.5.1 Company Overview
      8.5.2 Financial Overview
      8.5.3 Product Portfolio
      8.5.4 Business Strategies
8.6 CardioFocus, Inc.
      8.6.1 Company Overview
      8.6.2 Product Portfolio
8.7 Endoscopic Technologies, Inc.
      8.7.1 Company Overview
      8.7.2 Product Portfolio
      8.7.3 Business Strategies
8.8 Sanofi Aventis
      8.8.1 Company Overview
      8.8.2 Financial Overview
      8.8.3 Product Portfolio
      8.8.4 Business Strategies
8.9 St. Jude Medical, Inc.
      8.9.1 Company Overview
      8.9.2 Financial Overview
      8.9.3 Product Portfolio
      8.9.4 Business Strategies
8.10 Johnson and Johnson Ltd
      8.10.1 Company Overview
      8.10.2 Financial Overview
      8.10.3 Product Portfolio
      8.10.4 Business Strategies

List of Figures 

FIG. 1 Market Segmentation: Global Atrial Fibrillation Market
FIG. 2 Global Atrial Fibrillation Market, by Treatment Types, 2012 (USD Million)
FIG. 3 Global Population, by Age-Group, 2000 & 2050 (%)
FIG. 4 Porter’s Five Forces Analysis for the Global Atrial Fibrillation Market
FIG. 5 Comparative Analysis of the Global Atrial Fibrillation Market, by Treatment Types, 2012 & 2019 (%)
FIG. 6 Global Atrial Fibrillation Market, 2011 – 2019 (USD Million)
FIG. 7 Global Pharmacological Treatment for Atrial Fibrillation Market, 2011 – 2019 (USD Million)
FIG. 8 Global Anti-Arrhythmic Drugs Market, 2011 – 2019 (USD Million)
FIG. 9 Global Anti-Coagulant Drugs for Atrial Fibrillation Market, 2011 – 2019 (USD Million)
FIG. 10 Comparative Analysis of the Non-Pharmacological Treatment for Atrial Fibrillation Market
FIG. 11 Global Non-Pharmacological Treatment for Atrial Fibrillation Market, 2011 – 2019 (USD Million)
FIG. 12 Comparative Analysis: Catheter Ablation Treatment Types for the Atrial Fibrillation Market
FIG. 13 Global Catheter Ablation Treatment for Atrial Fibrillation Market, 2011 – 2019 (USD Million)
FIG. 14 Global Radiofrequency Based Catheter Ablation Treatment for Atrial Fibrillation Market, 2011 – 2019 (USD Million)
FIG. 15 Global HIFU (High Intensity Focused Ultrasound) Based Catheter Ablation Treatment for Atrial Fibrillation Market, 2011 – 2019 (USD Million)
FIG. 16 Global Cryoablation Based Catheter Ablation Treatment for Atrial Fibrillation Market, 2011 – 2019 (USD Million)
FIG. 17 Global Microwave Based Catheter Ablation Treatment for Atrial Fibrillation Market, 2011 – 2019 (USD Million)
FIG. 18 Global Laser Based Catheter Ablation Treatment for Atrial Fibrillation Market, 2011 – 2019 (USD Million)
FIG. 19 Global Maze Surgery for Atrial Fibrillation Market, 2013 – 2019 (USD Million)
FIG. 20 Global Electric Cardioversion for Atrial Fibrillation Market, 2011 – 2019 (USD Million)
FIG. 21 Comparative Analysis of the Global Atrial Fibrillation Market, by Geography, 2012 & 2019 (%)
FIG. 22 North America Atrial Fibrillation Market, 2011 – 2019 (USD Million)
FIG. 23 Europe Atrial Fibrillation Market, 2011 – 2019 (USD Million)
FIG. 24 Asia-Pacific Atrial Fibrillation Market, 2011 – 2019 (USD Million)
FIG. 25 RoW Atrial Fibrillation Market, 2011 – 2019 (USD Million)
FIG. 26 AtriCure Inc.: Annual Revenue, 2010 – 2012 (USD Million)
FIG. 27 Boehringer Ingelheim: Annual Revenue, 2010 – 2012 (USD Million)
FIG. 28 Boston Scientific: Annual sales revenue, 2010 – 2012 (USD Million)
FIG. 29 Bristol-Myers Squibb: Annual sales revenue, 2010 – 2012 (USD Million)
FIG. 30 Sanofi: Annual Revenue, 2010 – 2012 (USD Million)
FIG. 31 St. Jude Medical: Annual Sales Revenue,  2010 – 2012 (USD Million)
FIG. 32 Johnson and Johnson: Annual Revenue, 2010 – 2012 (USD Million)

List of Tables

TABLE 1 Market Snapshot: Global Atrial Fibrillation Market
TABLE 2 Impact analysis of the Market Drivers for the Global Atrial Fibrillation Market
TABLE 3 Impact analysis of the Market Restraints for the Global Atrial Fibrillation Market
TABLE 4 Anti-Arrhythmic Drug Types and Clinical Usage
TABLE 5 Anti-Arrhythmic Drugs: Classification and Clinical Usage
TABLE 6 North America Atrial Fibrillation Market, by Treatment Types, 2011 – 2019 (USD Million) 
TABLE 7 Europe Atrial Fibrillation Market, by Treatment Types, 2011 – 2019 (USD Million) 
TABLE 8 Asia-Pacific Atrial Fibrillation Market, by Treatment Types, 2011 – 2019 (USD Million) 
TABLE 9 RoW Atrial Fibrillation Market, by Treatment Types, 2011 – 2019 (USD Million)

Enquiry Before Buying




Free Market Analysis




The atrial fibrillation market on the basis of geography is segmented into four regions namely North America, Asia-Pacific, Europe and rest of the world (RoW). The North American atrial fibrillation market held majority of the market share in 2012 on account of the following factors:
  • High prevalence of atrial fibrillation. According to the estimates of the U.S. CDC, the prevalence of atrial fibrillation was 2.66 million in 2010. Moreover, its prevalence is estimated to reach 12 million by 2050.
  • The high atrial fibrillation prevalence coupled with the presence of high disposable incomes of patients, the presence of a robust reimbursement infrastructure and rising healthcare expenditure are some of the major factors driving the growth of North America atrial fibrillation market.
The North American region was followed by Europe in terms of market share in 2012. The Asia-Pacific atrial fibrillation market is expected to grow at the highest CAGR on account of the rising prevalence of atrial fibrillation in China coupled with the introduction of new healthcare reforms and rapid economic development in the country.  

In terms of treatment types, the overall atrial fibrillation market is segmented into two type’s namely pharmacological and non-pharmacological treatment markets. The global atrial fibrillation treatment market was dominated by the pharmacological treatment procedures (involving anti-arrhythmic drugs, rate control drugs, chemical cardioversion and anti-coagulants) in terms of market share in 2012. This valuation is justified by the following reasons:
  • Drugs are consumed more frequently by patients, sometimes simultaneously with non-pharmacological treatment procedures. For e.g. patients are advised to consume anti-coagulant drugs before an electric cardioversion and patients are administered with anti-coagulants post a catheter ablation procedure to reduce the risk of a stroke.
  • Drugs are a cheaper alternative to expensive non-pharmacological procedures such as catheter ablation and surgeries. However, this fact is not applicable to all the patients as in most of the cases cardiologists recommend the most appropriate and therefore inevitable treatment procedures to patients suffering from atrial fibrillation.
The market share of pharmacological treatment procedures is expected to increase to over 55% in 2019 on account of the introduction of new and advanced drugs such as anti-coagulants dabigatran and rivaroxaban.

global-atrial-fibrillation-market-by-treatment-types-2011-2019
 

To get discount on this report, just click on the button below.

To receive brochure, please click on the button below.

Share This Market Study!  

Upcoming Report

Payment
Copyright @ Transparency Market Research